# Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients

> **NCT01895335** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 1001 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Teriflunomide

## Key facts

- **NCT ID:** NCT01895335
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 1001 (ACTUAL)
- **Last updated:** 2016-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01895335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01895335, "Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01895335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*